DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Sympathomimetic amines (Cont.):
for shock, 301
structure-activity relationship of,
278–281
substitution on α-carbon, 281
substitution on aromatic nucleus,
281
substitution on β-carbon, 281
therapeutic uses of, 300–304
for weight loss, 303
Sympathomimetics, classification of,
274–277
Sympathomimetic toxidrome, 83t
Symport, 674
Symporters, 95
SYNALAR (fluocinolone acetonide),
1225t
SYNALAR-HP (fluocinolone acetonide
cream), 1225t
Synaptic vesicles, 184
Synaptobrevin, 184
Synaptosomal protein 25 (SNAP-25),
184, 187, 197f
SYNAREL (nafarelin), 1119t, 1764t,
1840
Syndrome of inappropriate antidiuretic
hormone secretion (SIADH),
711–712
vasopressin and, 711–712
Synergistic interaction, 77
Synonymous polymorphisms, 148,
155t
Syntaxin 1, 184
Synthetic organic chemistry, in history
of drug development, 3–4
SYNTOCINON (oxytocin), 1850
Syphilis
penicillin for, 1486–1487
primary/secondary, 1842t
prophylaxis for, 1488
tertiary, 1842t
Syrup of ipecac, 84
Systemic carnitine deficiency
syndrome, 102t, 113
Systemic lupus erythematosus (SLE)
bullous, dapsone for, 1823
with multi-system disease,
methylprednisolone sodium
succinate for, 1809
T
Tabun, 239, 243
Tachyarrhythmias, 820
Tachycardia
atropine and, 228
drug-induced, 821t
Tachyphylaxis, 199, 1806
Tacrine
polymorphisms and response to,
160t
structure of, 243f
Tacrolimus
ABC transporters and, 105t
adverse effects and side effects of,
1822
arrhythmias caused by, 832
for Behçet’s disease, 1822
in dermatology, 1822
formulations, 1822
in immunosuppressive therapy,
1008–1009
mechanism of action of, 1820t, 1822
pharmacokinetics of, 1890t
polymorphisms and response to, 159t
for psoriasis, 1822
for pyoderma gangrenosum, 1822
structure of, 1822
systemic, 1822
topical, 1822
Tadalafil, 758–759, 1061
effects on optic nerve, 1792
pharmacokinetics of, 1890t
Taenia saginata, 1447
Taenia solium, 1447–1448
TAK-442, 866
Taloxifene, 1756
TAMBOCOR (flecainide), 840–841
TAMIFLU (oseltamivir), 1596t
Tamoxifen, 1177–1180, 1668t–1670t,
1756–1759
absorption, fate, and excretion of,
1757
benefits of, 1759
and endometrial cancer, 1758
hepatotoxicity of, 1759
mechanism of action of, 1757
metabolism of, 128t
metabolites, 1758f
ocular effects of, 1759
pharmacokinetics of, 1891t
polymorphisms and response to,
159t
resistance to, 1759
retinal effects of, 1792
structure of, 1758f
therapeutic uses of, 1757–1758,
1757t
and thromboembolism, 1758
toxicity of, 1758–1759
Tamoxifen analogs, 1756
Tamsulosin, 306f, 307
pharmacokinetics of, 1891t
Tangier disease, 104t
Tapentadol, 510
TARCEVA (erlotinib), 1735
Tardive dyskinesia, in antipsychotic
drug therapy, 437t
Target polymorphisms, 162–163
Targets of drug action, 5–6
Target validation, 6
TARGRETIN (bexarotene), 1811, 1812
TASIGNA (nilotinib), 1732
Taurolithocholate sulfate, ABC
transporters and, 105t
TAVIST (clemastine fumarate), 921t
Taxanes, for neoplastic disease,
1668t–1670t, 1707–1709
Tazarotene, 1809-1811, 1810t
formulation, 1810t
irritancy, 1810t
for photoaging, 1810
pregnancy category, 1810t
for psoriasis, 1810
receptor specificity, 1810t
structure of, 1810t
TAZIDIME (ceftazidime), 1496t
TAZORAC (tazarotene), 1810
T-cell activation inhibitors, for
psoriasis, 1824–1825
Tears, 1773
Teicoplanin, 1539–1542
TEKTURNA (aliskiren), 745, 799
TEKTURNA HCT, 786
Telbivudine, 1616–1617
Telenzepine, 232–233, 1316–1317
TELFAST (fexofenadine hydrochloride),
922t
Telithromycin, pharmacokinetics of,
1891t
Telmisartan, 738
as antihypertensive agent, 774t,
785–786
structure of, 737f
Temazepam
administration and uses of, 466t
structure of, 459t
Temocapril, 105t, 109–110
TEMOVATE (clobetasol propionate), 1225t
Temozolomide, 1668t–1670t, 1687
Temperature, body
ethanol and, 637
muscarinic antagonists and,
229–230
opioids and, 498
Temsirolimus, 1743
drug interactions with, 1744
pharmacokinetics of, 1891t
therapeutic uses of, 1744
2075
INDEX